← Patent-cliff monitor Loss of exclusivity April 2035 latest FDA-listed patent expiry
Company VERTEX PHARMACEUTICALS INC
Drug detail Brand name SYMDEKO (COPACKAGED) Active ingredient IVACAFTOR; IVACAFTOR, TEZACAFTOR Strength 75MG;75MG, 50MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval June 2019 Marketing status RX
Listed patents Patent Expires Type 10206877 April 2035 product 9012496 July 2033 use U-2248 10058546 July 2033 use U-3023 RE50453 July 2031 substance, product 10081621 March 2031 product 11578062 March 2031 product 12458635 August 2029 product 10646481 August 2029 product 11564916 August 2029 use U-3527 8415387 November 2027 use U-2246 8324242 August 2027 use U-2246 7776905 June 2027 substance, product 7495103 May 2027 substance, product 7645789 May 2027 substance, product 8598181 May 2027 use U-2246 8623905 May 2027 substance, product 10022352 April 2027 product 10239867 April 2027 substance, product 11639347 April 2027 substance, product 9974781 April 2027 product 9931334 December 2026 product 9670163 December 2026 product 8754224 December 2026 substance, product 8410274 December 2026 product 8354427 July 2026 use U-3021
Regulatory exclusivity Code Expires ODE-335 December 2027 ODE-247 June 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.